Temozolomide

Generic Name
Temozolomide
Brand Names
Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
Drug Type
Small Molecule
Chemical Formula
C6H6N6O2
CAS Number
85622-93-1
Unique Ingredient Identifier
YF1K15M17Y
Background

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication

Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions
Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
Associated Therapies
-
Clinical Trials
Related News

Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2004-05-26
Last Posted Date
2014-01-08
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT00006877
Locations
🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-25
Last Posted Date
2012-08-08
Lead Sponsor
Pfizer
Registration Number
NCT00004200
Locations
🇺🇸

Agouron Pharmaceuticals, Inc., La Jolla, California, United States

Temozolomide in Treating Patients With Recurrent Malignant Glioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-21
Last Posted Date
2013-06-19
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00004113
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

Phase 1
Conditions
Melanoma (Skin)
First Posted Date
2004-05-21
Last Posted Date
2013-09-20
Lead Sponsor
Mount Vernon Cancer Centre at Mount Vernon Hospital
Target Recruit Count
30
Registration Number
NCT00003747
Locations
🇬🇧

Mount Vernon Hospital, Northwood, England, United Kingdom

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-20
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
39
Registration Number
NCT00003731
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇳🇱

Academisch Ziekenhuis Utrecht, Utrecht, Netherlands

and more 21 locations

Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

First Posted Date
2004-05-17
Last Posted Date
2015-02-10
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
30
Registration Number
NCT00083096
Locations
🇫🇷

Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇫🇷

Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

Phase 1
Completed
Conditions
Leukemia
Interventions
Drug: temozolomide
First Posted Date
2004-05-17
Last Posted Date
2014-02-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
16
Registration Number
NCT00083070
Locations
🇺🇸

SUNY Upstate Medical University Hospital, Syracuse, New York, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

and more 13 locations

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

First Posted Date
2004-04-14
Last Posted Date
2014-01-06
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Target Recruit Count
25
Registration Number
NCT00003718
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer

First Posted Date
2004-04-08
Last Posted Date
2023-06-29
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
26
Registration Number
NCT00080938

Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-04-07
Last Posted Date
2018-06-27
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
82
Registration Number
NCT00003176
Locations
🇺🇸

Simmons Cancer Center - Dallas, Dallas, Texas, United States

🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy